ICIs for NSCLC: Patients With ILD Show Greater Risk

Immune checkpoint inhibitors can be effective in patients with non-small cell lung cancer and mild interstitial lung disease, but with a greater risk.

Related Keywords

China ,Beijing ,Maryland ,United States ,Yuan Cheng ,Guangdong ,Peking ,Baltimore ,Jarushka Naidoo ,Karthik Suresh ,University First Hospital ,Johns Hopkins School Of Medicine ,Sidney Kimmel Comprehensive Cancer Center ,Peking University First Hospital ,Medscape Medical ,East Asian ,Johns Hopkins School ,Lung Cancer ,Ung Carcinoma ,Ancer Lung ,Interstitial Lung Disease ,Non Small Cell Lung Cancer ,Nsclc ,Pneumonia ,Neoplasm ,Radiation Oncology ,Tumor ,Biologic Therapy ,Biologic Therapy In Cancer ,Iological Therapy In Cancer ,Iologics Cancer ,Computed Tomography ,It ,Meta Analysis ,Monoclonal Antibody ,Etuximab ,Ituximab ,Lung ,Chronic Obstructive Pulmonary Disease Copd ,Hronic Obstructive Pulmonar ,